{'fraction_non_alphanumeric': 0.01646090534979424, 'fraction_numerical': 0.00205761316872428, 'mean_word_length': 5.197452229299363, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Savings can be achieved if Ugandan company provides HIV drugs to employees.


 At the 13th International AIDS Conference in Durban, South Africa, it was reported that researchers have found that it may be cost-effective for Ugandan companies to provide HIV drugs to infected employees. The study team developed an economic model that considers the HIV-related costs to operating the business and then compares these costs with the costs of a more intensive preventive care program, accounting for anticipated savings in HIV treatment costs. Focusing on the costs and benefits of providing highly active antiretroviral treatment (HAART) and the preventive drug cotrimoxazole (PCTMX) to employees with HIV once they become symptomatic, the model reflects reductions in the costs of antiretrovirals for developing countries. Overall, the study concludes that it would save Ugandan companies money to fund the prophylactic PCTMX alone or along with HAART for skilled workers.
